Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Chronic Granulomatous Disease: early-phase trial registry

2 of 11 indexed Chronic Granulomatous Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Chronic Granulomatous Disease: 11 US clinical trials tracked, 2 recruiting.

Chronic Granulomatous Disease is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 6 of these trials.

Enrollment posture brief

Registry condition chronic-granulomatous-disease

OPEN 2 | RECR 18% | LATE 1 | EARLY 9 | RANK #1577 | SPON 6

Volume-matched condition peers

Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Chronic Granulomatous Di (th…18%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Chronic Granulomatous Disease

Chronic Granulomatous Disease lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Granulomatous Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Granulomatous Disease is recruiting below its size-band peers.

    2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chronic Granulomatous Disease research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 6 of 11 trials (54.5%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Chronic Granulomatous Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 20 among the 11 trials that report a genuine target (sentinel values excluded). 11 of those (100%) plan for fewer than 100 participants.

  4. Chronic Granulomatous Disease research is mostly interventional.

    11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 22Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1 50 participants

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05463133
RECRUITING Phase 1 25 participants

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05189925
ACTIVE NOT RECRUITING NA 57 participants

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Masonic Cancer Center, University of Minnesota

NCT01652092
ACTIVE NOT RECRUITING Phase 2 20 participants

Immune Disorder HSCT Protocol

Washington University School of Medicine

NCT01821781
ACTIVE NOT RECRUITING Phase 1 12 participants

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

Prime Medicine

NCT06559176
ACTIVE NOT RECRUITING Early Phase 1 7 participants

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05600907
ACTIVE NOT RECRUITING Early Phase 1 4 participants

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03910452
COMPLETED Phase 3 60 participants

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00023192
COMPLETED Phase 1 60 participants

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001765
COMPLETED Phase 1 20 participants

Effect of IFN-γ on Innate Immune Cells

University of Colorado, Denver

NCT02609932
COMPLETED Phase 2 15 participants

Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

Baylor College of Medicine

NCT00578643

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 2
Phase 3 1

Top Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 6 trials
Prime Medicine 1 trials
Washington University School of Medicine 1 trials
Masonic Cancer Center, University of Minnesota 1 trials
University of Colorado, Denver 1 trials
Baylor College of Medicine 1 trials

Named interventions

Most-linked intervention names on Chronic Granulomatous Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Busulfan Drug
4 trials
Cyclophosphamide Drug
4 trials
Alemtuzumab Drug
2 trials
Sirolimus Drug
2 trials
Administration of drug (Interferon-gamma 1-b) subcutaneously Drug
1 trials
Baxter isolex 300i Device
1 trials
Nexell Isolex with T-cell Depletion Device
1 trials
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product Drug
1 trials

US sites by state

Facility locations filed on Chronic Granulomatous Disease trials. A trial with sites in several states counts in each.

Maryland 7 trials
Texas 1 trials
Tennessee 1 trials
Missouri 1 trials
Minnesota 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Chronic Granulomatous Disease page

11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Granulomatous Disease condition card totals 11 registered trials; most-linked intervention Busulfan; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.